Results 1 to 10 of about 35,838 (264)

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer [PDF]

New England Journal of Medicine, 2019
BACKGROUND Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor.
Shanu Modi, Cristina Saura, Toshinari Yamashita, Yeon Hee Park, Sung‐Bae Kim, Kenji Tamura, Fabrice André, Hiroji Iwata, Yoshinori Ito, Junji Tsurutani, Joohyuk Sohn, Neelima Denduluri, Christophe Perrin, Kenjiro Aogi, Eriko Tokunaga, Seock‐Ah Im, Keun Seok Lee, Sara A. Hurvitz, Javier Cortés, Caleb Lee, Shuquan Chen, Lin Zhang, Javad Shahidi, Antoine Yver, Ian E. Krop   +24 more
semanticscholar   +7 more sources

Fam-trastuzumab deruxtecan-nxki (Enhertu®): A narrative drug review

Cancer Research, Statistics, and Treatment, 2022
Human epidermal growth factor receptor 2 (HER2) is a subset of the epidermal growth factor receptor family that expresses tyrosine kinase activity. Dimerization of the receptor initiates various cellular signaling pathways, ultimately leading to the ...
Ryan Varghese, Niraja Soman, Jainam Karsiya, Nimesh Bafna, Shona Nag   +4 more
doaj   +6 more sources

The efficacy of trastuzumab deruxtecan in Chinese breast cancer patients: a real-world multicenter study [PDF]

Frontiers in Oncology
IntroductionIn mainland China, trastuzumab deruxtecan was first authorized in February 2023 as a monotherapy for the treatment of patients with HER-2-positive adult breast cancer who were either unresectable or had metastasized after receiving one or ...
Miao He, Miao He, Xiaohui Liu, Yan Zhang, Zhenyu Shao, Tiantian Sun, Yu Hu   +6 more
doaj   +2 more sources

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer [PDF]

New England Journal of Medicine, 2022
METHODS We conducted a phase 3 trial involving patients with HER2-low metastatic breast cancer who had received one or two previous lines of chemotherapy. (Low expression of HER2 was defined as a score of 1+ on immunohistochemical [IHC] analysis or as an
S. Modi, W. Jacot, T. Yamashita, J. Sohn, M. Vidal, E. Tokunaga, J. Tsurutani, N. Ueno, A. Prat, Y. Chae, K. Lee, N. Niikura, Yeon-Hee Park, Bing-he Xu, Xiao-juan Wang, M. Gil-Gil, Wei Li, J. Pierga, S. Im, H. Moore, H. Rugo, R. Yerushalmi, F. Zagouri, A. Gombos, Sung-Bae Kim, Qiang Liu, T. Luo, C. Saura, P. Schmid, T. Sun, D. Gambhire, L. Yung, Yibin Wang, Jasmeet Singh, P. Vitazka, G. Meinhardt, N. Harbeck, D. Cameron   +37 more
semanticscholar   +6 more sources

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

Journal of Clinical Oncology, 2023
PURPOSE Trastuzumab deruxtecan (T-DXd) is a human epidermal growth factor 2 (HER2)–directed antibody-drug conjugate approved in HER2-expressing breast and gastric cancers and HER2-mutant non–small-cell lung cancer.
Funda Meric‐Bernstam, Vicky Makker, Ana Oaknin, Do‐Youn Oh, Susana Banerjee, Antonio González-Martı́n, Kyung Hae Jung, Iwona Ługowska, Luís Manso, Aránzazu Manzano, Bohuslav Melichar, Salvatore Siena, Daniil Stroyakovskiy, Anitra Fielding, Yan Ma, Soham D. Puvvada, Norah J. Shire, Jung‐Yun Lee   +17 more
openalex   +2 more sources

Successful Rechallenge of Trastuzumab Deruxtecan After Drug-Induced Interstitial Lung Disease in a NSCLC With HER2 Mutation: A Case Report

JTO Clinical and Research Reports, 2023
Trastuzumab deruxtecan, an antibody-drug conjugate targetingHER2-expressing tumor cells, was found to have promising results in treatment-refractory, metastatic NSCLC harboring HER2 mutations.
Sangho Nam, MD, Sun Min Lim, MD, PhD, Byoung Chul Cho, MD, PhD, Jii Bum Lee, MD   +3 more
doaj   +2 more sources

Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial

Nature Medicine, 2023
The mechanisms of action of and resistance to trastuzumab deruxtecan (T-DXd), an anti-HER2–drug conjugate for breast cancer treatment, remain unclear. The phase 2 DAISY trial evaluated the efficacy of T-DXd in patients with HER2-overexpressing ( n  = 72,
Fernanda Mosele, Elise Deluche
exaly   +2 more sources

Comparative pharmacological analysis of fam-trastuzumab deruxtecan-nxki and sacituzumab govitecan-hziy: Two recently developed chemotherapies in the crucial battle against breast cancer [PDF]

Toxicology Reports
This study provides a detailed pharmacological evaluation of the recently approved antibody-drug conjugates (ADCs), fam-trastuzumab deruxtecan-nxki and sacituzumab govitecan-hziy, focusing on their adverse event (AE) profiles post-approval by the United ...
Amjad Z. Alrosan, Isra Dmour, Aseel O. Rataan, Ghaith B. Heilat, Khaled Alrosan   +4 more
doaj   +2 more sources

Successful Treatment of HER2 V659E Mutation‐Positive Lung Adenocarcinoma With Trastuzumab Deruxtecan: A Case Report [PDF]

Thoracic Cancer
A 67‐year‐old patient with metastatic lung adenocarcinoma harboring a HER2 V659E mutation received trastuzumab deruxtecan (T‐DXd) as second‐line treatment. The V659E mutation is a rare alteration located in the transmembrane domain of HER2. The antitumor
Mariko Nishihara, Yuki Shinno, Yoshihiro Masui, Ken Masuda, Yuji Matsumoto, Yusuke Okuma, Tatsuya Yoshida, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Yuichiro Ohe   +10 more
doaj   +2 more sources

Evaluating risk factors for Trastuzumab-Deruxtecan Pneumonitis in patients with metastatic breast cancer [PDF]

Breast Cancer Research
Background Trastuzumab deruxtecan (T-DXd) is FDA-approved for treatment of patients with HER2 positive and HER2-low metastatic breast cancer. Currently, there is limited understanding of pre-treatment risk factors for pneumonitis associated with T-DXd ...
Jonathan Henricks, Tyler Haddad, Omair Ahmed, Jonathan Schoenhals, Pavnesh Kumar, Ryan Wilson, Jianing Ma, Jing Gennie Wang, Michael Wert, Vincent Esguerra, Ian Bentley, Kai Johnson, Daniel Stover, Sachin R. Jhawar, Margaret Gatti-Mays, Kevin Ho   +15 more
doaj   +2 more sources